Baseline characteristics of men with prostate cancer and randomly selected men free of prostate cancer from the general population matched on birth year and geographical region in PCBaSe V.4.0
| Men with prostate cancer N=92 105 | Men without prostate cancer N=466 241 | |
| Age (years), median (IQR) | 69 (64–76) | 69 (64–76) |
| Educational level | ||
| Low (<9 years) | 30 977 (33.6) | 166 338 (35.7) |
| Middle (9–12 years) | 36 472 (39.6) | 182 575 (39.2) |
| High (>12 years, university) | 23 955 (26.0) | 110 787 (23.8) |
| Missing | 701 (0.8) | 6541 (1.4) |
| Marital status | ||
| Married | 60 323 (65.5) | 286 441 (61.4) |
| Unmarried | 10 714 (11.6) | 66 971 (14.4) |
| Divorced | 13 859 (15) | 76 631 (16.4) |
| Widower | 7169 (7.8) | 36 186 (7.8) |
| Missing | 40 (0.04) | 12 (0) |
| Charlson Comorbidity Index | ||
| 0 | 70 303 (76.3) | 341 974 (73.3) |
| 1 | 11 835 (12.8) | 63 565 (13.6) |
| 2 | 5485 (6) | 31 184 (6.7) |
| 3 | 2213 (2.4) | 13 938 (3.0) |
| ≥4 | 2269 (2.5) | 15 580 (3.3) |
| Mean (SD) | 0.5 (1.1) | 0.5 (1.2) |
| Comorbidities* | ||
| Hypertension | 22 932 (24.9) | 116 690 (25.0) |
| Valvular heart disease | 2795 (3.0) | 15 379 (3.3) |
| Coronary artery disease | 13 163 (14.3) | 74 009 (15.9) |
| Angina pectoris | 9154 (9.9) | 50 474 (10.8) |
| Myocardial infarction | 7633 (8.3) | 44 622 (9.6) |
| Peripheral arterial disease | 2989 (3.2) | 18 516 (4.0) |
| Atrial fibrillation | 8628 (9.4) | 47 540 (10.2) |
| Chronic heart failure | 4642 (5.0) | 30 040 (6.4) |
| Peripheral systemic embolism | 261 (0.3) | 1570 (0.3) |
| Haemorrhagic stroke | 1077 (1.2) | 6647 (1.4) |
| Ischaemic stroke | 4298 (4.7) | 26 604 (5.7) |
| Stroke NOS | 1231 (1.3) | 8425 (1.8) |
| TIA | 2990 (3.2) | 15 721 (3.4) |
| Diabetes mellitus | 7897 (8.6) | 51 139 (11) |
| Hyperlipidaemia | 574 (9.3) | 46 220 (9.9) |
| Cancer | 12 261 (13.3) | 30 942 (6.6) |
| Obstructive sleep apnoea | 1370 (1.5) | 7396 (1.6) |
| COPD | 2599 (2.8) | 15 250 (3.3) |
| Bleedings | ||
| Intracranial | 1293 (1.4) | 7900 (1.7) |
| Upper gastrointestinal | 1904 (2.1) | 9787 (2.1) |
| Lower gastrointestinal | 626 (0.7) | 3061 (0.7) |
| Urogenital | 4251 (4.6) | 15 829 (3.4) |
| Medications† | ||
| Antiarrhythmics | 463 (0.5) | 2270 (0.5) |
| Statins | 22 355 (24.3) | 115 697 (24.8) |
| Cardiovascular drugs‡ | 82 267 (89.3) | 414 211 (88.8) |
| Antidiabetics | 8364 (9.1) | 53 108 (11.4) |
| NSAIDs | 10 875 (11.8) | 35 896 (7.7) |
| Antiplatelet drugs | 19 870 (21.6) | 105 195 (22.6) |
| Vitamin K antagonists | 4516 (4.9) | 24 725 (5.3) |
| DOACs | 604 (0.7) | 3320 (0.7) |
| Parenteral anticoagulant | 2073 (2.3) | 3346 (0.7) |
Data are n (%) unless otherwise stated.
*Comorbidities were identified through International Classification of Diseases, 10th Revision, codes in the National Patient Register as the main or secondary diagnosis any time before the index date.
†Medications were identified by ATC Classification codes in the Drug Prescription Register during the 120 days before the index date.
‡Includes beta blockers, calcium-channel blockers, ACE inhibitors, angiotensin II receptor blockers and diuretics.
ACE, angiotensin-converting enzyme; ATC, Anatomical Therapeutic Chemical Classification; COPD, chronic obstructive pulmonary disease; DOAC, direct oral anticoagulant; NOS, not otherwise specified; NSAID, non-steroidal anti-inflammatory drug; PCBaSe, Prostate Cancer data Base Sweden; TIA, transient ischaemic attack.